A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03719326 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer
Ovarian Cancer

Interventions

DRUG: Etrumadenant
DRUG: IPI-549
DRUG: Pegylated liposomal doxorubicin (PLD)
DRUG: nanoparticle albumin-bound paclitaxel (NP)

Sponsor

Arcus Biosciences, Inc.

Collaborators

[object Object]